Article
Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
European journal of cancer (Oxford, England : 1990) - 1 Oct 2020
Langer Thorsten, Clemens Eva, Broer Linda, Maier Lara, Uitterlinden André G, de Vries Andrica C H, van Grotel Martine, Pluijm Saskia F M, Binder Harald, Mayer Benjamin, von dem Knesebeck Annika, Byrne Julianne, van Dulmen-den Broeder Eline, Crocco Marco, Grabow Desiree, Kaatsch Peter, Kaiser Melanie, Spix Claudia, Kenborg Line, Winther Jeanette F, Rechnitzer Catherine, Hasle Henrik, Kepak Tomas, van der Kooi Anne-Lotte F, Kremer Leontien C, Kruseova Jarmila, Bielack Stefan, Sorg Benjamin, Hecker-Nolting Stefanie, Kuehni Claudia E, Ansari Marc, Kompis Martin, van der Pal Heleen, Parfitt Ross, Deuster Dirk, Matulat Peter, Tillmanns Amelie, Tissing Wim J E, Beck Jörn D, Elsner Susanne, Am Zehnhoff-Dinnesen Antoinette, van den Heuvel-Eibrink Marry M, Zolk Oliver
Abstract excerpt
BACKGROUND: Irreversible sensorineural hearing loss is a common side effect of platinum treatment with the potential to significantly impair the neurocognitive, social and educational development of childhood cancer survivors. Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical...
Read the complete abstract on PubMed